Matt Hewitt
Stock Analyst at Craig-Hallum
(2.69)
# 1,906
Out of 5,182 analysts
44
Total ratings
55.26%
Success rate
2.85%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MXCT MaxCyte | Maintains: Buy | $7 → $5 | $0.79 | +531.79% | 2 | Mar 25, 2026 | |
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $13.04 | +176.07% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $5.75 | +108.70% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $1.93 | +210.88% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $19.74 | +62.11% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $34.40 | +86.05% | 6 | Oct 31, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $204.92 | -31.68% | 3 | Jul 9, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $0.23 | +4,264.91% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $11.37 | +163.85% | 3 | May 2, 2024 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $120.10 | +66.53% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.47 | +580.27% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $5.10 | +488.24% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.13 | +312,156.05% | 1 | Jan 4, 2022 |
MaxCyte
Mar 25, 2026
Maintains: Buy
Price Target: $7 → $5
Current: $0.79
Upside: +531.79%
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $13.04
Upside: +176.07%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $5.75
Upside: +108.70%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $1.93
Upside: +210.88%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $19.74
Upside: +62.11%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $34.40
Upside: +86.05%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $204.92
Upside: -31.68%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $0.23
Upside: +4,264.91%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $11.37
Upside: +163.85%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $120.10
Upside: +66.53%
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.47
Upside: +580.27%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $5.10
Upside: +488.24%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $0.13
Upside: +312,156.05%